Afuco™ Anti-CD40LG ADCC Therapeutic Antibody (Ruplizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human CD40L. Ruplizumab is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-027 |
| Pricing | Inquiry |
| Host | Human |
| Target | CD40LG |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | IF, IP, Neut, FuncS, ELISA, FC |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |